[Tailor-made medicine and genomic drug discovery in rheumatoid arthritis].
Taniguchi
Atsuo
A
Institute of Rheumatology, Tokyo Women's Medical University.
Kamatani
Naoyuki
N
D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics*; D001191:Arylamine N-Acetyltransferase / Q000235:genetics; D015195:Drug Design; D015894:Genome, Human; D006239:Haplotypes; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics; D010597:Pharmacogenetics; D012460:Sulfasalazine / Q000627:therapeutic use
D018501:Antirheumatic Agents; D012460:Sulfasalazine; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D001191:Arylamine N-Acetyltransferase; C478900:NAT2 protein, human; D008727:Methotrexate